Osteonecrosis of the jaw secondary to oral alendronate: Report of three cases

Osteonecrosis of the jaw associated to biphosphonate use is more common in cancer patients with bone metastases, that are using intravenous diphosphonates. When these drugs are used orally the risk of the complication is lower. We report 3 diabetic women aged 69, 76 and 82 years, receiving alendrona...

Full description

Saved in:
Bibliographic Details
Published in:Revista medíca de Chile 2009-02, Vol.137 (2), p.275-279
Main Authors: Bocanegra-Pérez, Sacramento, Vicente-Barrero, Mario, Sosa-Henríquez, Manuel, Gebaguer Blanco, Arwen, Knezevic, Milán, Castellano-Navarro, José María
Format: Article
Language:Spanish
Subjects:
Aged
Aged, 80 and over
Alendronate - adverse effects
Bone Density Conservation Agents - adverse effects
Diabetes Mellitus, Type 2 - drug therapy
Female
Humans
Jaw Diseases - chemically induced
Maxillary Diseases - chemically induced
Osteonecrosis - chemically induced
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Osteonecrosis of the jaw associated to biphosphonate use is more common in cancer patients with bone metastases, that are using intravenous diphosphonates. When these drugs are used orally the risk of the complication is lower. We report 3 diabetic women aged 69, 76 and 82 years, receiving alendronate 70 mg every one week. The unveiling event was the extraction of several teeth without the use of antibiotics. All had bone pain, purulent discharge, loss of bone and halitosis. All improved five months after discontinuing alendronate.
ISSN:0034-9887